Cargando…

OR21-01 Pre-treatment Blood Transcriptome Predicts First-year Growth And IGF-I Response To Somapacitan Treatment In Children With GH Deficiency

Disclosure: T. Garner: Grant Recipient; Self; Novo Nordisk. P.E. Clayton: Grant Recipient; Self; Novo Nordisk. M. Hojby: Employee; Self; Novo Nordisk. Stock Owner; Self; Novo Nordisk. P. Murray: Grant Recipient; Self; Novo Nordisk. A. Stevens: Grant Recipient; Self; Novo Nordisk. Background: Growth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garner, Terence, Clayton, Peter Ellis, Hojby, Michael, Murray, Philip, Stevens, Adam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Pediatric Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555074/ http://dx.doi.org/10.1210/jendso/bvad114.1519

Ejemplares similares

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2023)

RF14 | LBMON195 Once-weekly Somapacitan Is Effective And Well Tolerated In Children With GH Deficiency: A Randomized Phase 3 Trial
por: Miller, Bradley, et al.
Publicado: (2022)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

SAT-091 First Report of Disease-Specific Patient-Reported Outcomes from a Randomized Phase 2 Trial of Once-Weekly Somapacitan vs Daily GH in Children with GHD
por: Brod, Meryl, et al.
Publicado: (2020)

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency
por: Kildemoes, Rasmus J, et al.
Publicado: (2023)

SAT-LB12 Once-Weekly Somapacitan vs Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Safety Results From Real 3, a Randomized Phase 2 Trial
por: Savendahl, Lars S, et al.
Publicado: (2020)

SUN-247 Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Efficacy and Safety Results of a Randomized, Open-Label, Controlled Phase 2 Trial (REAL 3)
por: Savendahl, Lars, et al.
Publicado: (2019)

RF26 | PMON334 Once-Weekly Somapacitan in Growth Hormone Deficiency: 4-Year Efficacy and Safety Results from REAL 3, a Randomised Controlled Phase 2 Trial
por: Savendahl, Lars, et al.
Publicado: (2022)

Diagnosis of Childhood and Adolescent Growth Hormone Deficiency Using Transcriptomic Data
por: Garner, Terence, et al.
Publicado: (2021)

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2023)

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial
por: Sävendahl, Lars, et al.
Publicado: (2020)

MON-265 Once-Weekly Somapacitan in Japanese Adults with GH Deficiency Was Well Tolerated, with Similar Efficacy to Daily GH: A Randomized Trial
por: Otsuka, Fumio, et al.
Publicado: (2020)

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
por: Johannsson, Gudmundur, et al.
Publicado: (2020)

RF26 | PMON335 Once-Weekly Somapacitan Versus Daily Growth Hormone in Children Born Small for Gestational Age: Results From a Randomized Phase 2 Trial
por: Juul, Anders, et al.
Publicado: (2022)

SAT642 Effective Gh Replacement With Once-weekly Somapacitan In Children With Gh Deficiency: 2-year Results From Real4
por: Miller, Bradley Scott, et al.
Publicado: (2023)

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial
por: Miller, Bradley S, et al.
Publicado: (2022)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2021)

Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
por: Bidlingmaier, Martin, et al.
Publicado: (2022)

Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
por: Bidlingmaier, Martin, et al.
Publicado: (2023)

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH
por: Miller, Bradley S, et al.
Publicado: (2023)

SUN-248 Growth Hormone Deficiency (GHD): Assessing Burden of Treatment in Children and Adolescents
por: Brod, Meryl, et al.
Publicado: (2019)

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan
por: Juul Kildemoes, Rasmus, et al.
Publicado: (2020)

SUN-260 The Severity of GH Deficiency (GHD) Does Not Affect Adherence to Treatment in GHD Prepubertal Children Taking rh-GH via the Easypod Device
por: Loche, Sandro, et al.
Publicado: (2019)

Diagnosis of childhood and adolescent growth hormone deficiency using transcriptomic data
por: Garner, Terence, et al.
Publicado: (2023)

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial
por: Johannsson, Gudmundur, et al.
Publicado: (2018)

Antenatal Markers Related to Fetal Growth Restriction Can Predict Childhood Systolic Blood Pressure
por: Perchard, Reena, et al.
Publicado: (2021)

LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency
por: Bright, George, et al.
Publicado: (2021)

Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2021)

Inside the Noonan “universe”: Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns
por: Stagi, Stefano, et al.
Publicado: (2022)

OR10-02 Diagnosis of Severe GH Deficiency in Newborns: New Reference Range for the Preterm and Confirmation of the GH Cut-Off
por: Binder, Gerhard, et al.
Publicado: (2020)

Diagnosis of Idiopathic GHD in Children Based on Response to rhGH Treatment: The Importance of GH Provocative Tests and IGF-1
por: Felício, João Soares, et al.
Publicado: (2019)

OR14-1 Preimplantation embryo development is associated with both birth size and post-natal growth and can predict adult cardiovascular risk
por: Brison, Daniel, et al.
Publicado: (2022)

OR21-03 Dose Responsiveness Of LUM-201 As Measured By Acute GH Response And IGF-1 And Annualized Height Velocity (AHV) Measured At 6 Months In The Interim Analysis Of The OraGrowtH212 Study In Idiopathic Pediatric Growth Hormone Deficiency (iPGHD)
por: Cassorla, Fernando, et al.
Publicado: (2023)

The crosstalk between FGF21 and GH leads to weakened GH receptor signaling and IGF1 expression and is associated with growth failure in very preterm infants
por: Mistry, Jayna N., et al.
Publicado: (2023)

THU157 Epigenetic Regulation Of Genes Involved In The Signaling Cascade Of The GH Axis - IGF1 And Insulin. Implication In Children Postnatal Growth
por: Zoff, Luciana, et al.
Publicado: (2023)

Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
por: Miller, Bradley S, et al.
Publicado: (2023)

Corrigendum to: “Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial”
Publicado: (2020)

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
por: Takahashi, Yutaka, et al.
Publicado: (2022)

Diagnosis of GH Deficiency Without GH Stimulation Tests
por: Ibba, Anastasia, et al.
Publicado: (2022)

OR10-04 Interpretation of Insulin-like Growth Factor-1 (IGF-1) Levels Following Administration of Somatrogon (a Long-acting Human Growth Hormone - hGH-CTP)
por: Fisher, Dennis M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o3lchdi2p0qo61hqmecsvlro9s